SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Nectar Lifesciences - Quaterly Results

30 May 2022 Evaluate
The sales surged to Rs. 4762.33 millions, up 36.55% for the March 2022 quarter as against Rs. 3487.53 millions during the corresponding quarter previous year.The Total Profit for the quarter ended March 2022 of Rs. 116.58 millions grew from Rs.-409.60 millionsThe company reported a good operating profit of 496.70 millions compared to 302.61 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 4762.33 3487.53 36.55 16682.56 15428.96 8.12 16682.56 15428.96 8.12
Other Income 5.20 10.19 -48.97 112.93 27.22 314.88 112.93 27.22 314.88
PBIDT 496.70 302.61 64.14 1701.31 1129.49 50.63 1701.31 1129.49 50.63
Interest 174.31 256.46 -32.03 788.10 1120.32 -29.65 788.10 1120.32 -29.65
PBDT 322.39 -207.00 -255.74 913.21 -243.98 -474.30 913.21 -243.98 -474.30
Depreciation 142.57 150.08 -5.00 569.68 602.53 -5.45 569.68 602.53 -5.45
PBT 179.82 -357.08 -150.36 343.53 -846.51 -140.58 343.53 -846.51 -140.58
TAX 63.24 52.52 20.41 90.34 -115.04 -178.53 90.34 -115.04 -178.53
Deferred Tax 63.24 -33.34 -289.68 90.34 -200.90 -144.97 90.34 -200.90 -144.97
PAT 116.58 -409.60 -128.46 253.19 -731.47 -134.61 253.19 -731.47 -134.61
Equity 224.26 224.26 0.00 224.26 224.26 0.00 224.26 224.26 0.00
PBIDTM(%) 9.07 7.43 22.12 8.84 6.41 37.98 8.84 6.41 37.98

Nectar Lifesciences Share Price

12.26 0.32 (2.68%)
15-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.65
Dr. Reddys Lab 1218.30
Cipla 1226.65
Zydus Lifesciences 936.00
Lupin 2339.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×